CARDIOVASCULAR DISEASES & CARDIOMETABOLIC COMPLICATIONS
Cardiomedex is a highly skilled preclinical CRO specialized in the cardiovascular field. Cardiomedex conducts reliable studies that optimize the preclinical development of drug candidates for the treatment of cardiovascular diseases and cardiometabolic complications.
Our large selection of gold standard animal models covers cardiovascular disorders such as:
- Heart failure with preserved or reduced ejection fraction (HFpEF and HFrEF)
- Myocardial infarction
- Cardiac hypertrophy
- Endothelial dysfunction
- Anthracycline cardiotoxicity
In addition to CRO services, we provide our clients with personalized consulting services in line with the pharma industry’s emerging trends.
Thanks to their extensive experience in drug development, our scientists and clinicians are able to optimize research timelines and productivity. Cardiomedex can also support your projects in terms of drug repurposing / repositioning.
Cardiomedex is located near Toulouse (France) and shares brand new facilities with Physiogenex. Our technical platform is equipped with all the appropriate devices to ensure high-quality CRO services and reliable study results for our clients.
Along with in vivo models, we offer a state-of-the-art platform for functional exploration & pharmacological characterization using ex-vivo and in vitro assays.
Preclinical CRO Services
Cardiomedex’s objective is to provide relevant and innovative animal models reflecting the clinical situation for the purpose of predictive efficacy studies. Lack of medicines to manage cardiac diseases such as HFpEF prompts us to develop translational models with multiple common risk factors such as NASH, diabetic nephropathy, metabolic syndrome, and type 2 diabetes.
Physiogenex and Cardiomedex to present the SDT fatty rat model at ISN-World Congress of Nephrology in Bangkok, Thailand, March 30-April 2, 2023
Physiogenex, its subsidiary company Cardiomedex, and its partner CLEA Japan Inc., will be presenting their collaborative work at the ISN-World Congress of Nephrology, to be held March 30-April 2 in Bangkok, Thailand. Dr. François Briand, Director of Research and...
Physiogenex and Cardiomedex to present a new diabetic NASH HFpEF hamster model at the Keystone conference on type 2 Diabetes therapeutics, May 1-4 in Palm Springs, CA, USA
Physiogenex and its subsidiary company Cardiomedex will be presenting a new diabetic NASH HFpEF hamster model at the Keystone Symposia on type 2 diabetes therapeutics in Palm Springs, CA, USA May 1-4, 2023. This unique preclinical model will be presented during the...
- Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters.
Briand F, Maupoint J, Brousseau E, Breyner N, Bouchet M, Costard C, Leste-Lasserre T, Petitjean M, Chen L, Chabrat A, Richard V, Burcelin R, Dubroca C, Sulpice T. Metabolism. 2021 Jan 11;117:154707.
- Liraglutide shows superior cardiometabolic benefits than lorcaserin in a novel free choice diet-induced obese rat model. Eur J Pharmacol. 2020 Sep 5;882:173316
Briand F, Brousseau E, Maupoint J, Dubroca C, Costard C, Breyner N, Burcelin R, Sulpice T. 2020 Sep 5;882:173316.
- Neuronal NO synthase mediates phenylephrine induced cardiomyocyte hypertrophy through facilitation of NFAT-dependent transcriptional activity.
Loyer X, Dubroca C, Branchereau M, Griffith G, Garcia L, Heymes C. Biochem Biophys Rep. 2019 Mar 11;18:100620.
They trust US
CONTACT US FOR MORE INFORMATION